Nanotech 2008 Vol. 2
Nanotech 2008 Vol. 2
Nanotechnology 2008: Life Sciences, Medicine & Bio Materials - Technical Proceedings of the 2008 NSTI Nanotechnology Conference and Trade Show, Volume 2

Drug & Gene Delivery Systems Chapter 4

Systemic Delivery of Targeted, siRNA-Containing Nanoparticles for the Treatment of Solid Tumors: Concept to Clinic

Authors: J.D. Heidel, J.Y-C. Liu, R.K. Zeidan, Y. Liang, S. Rele, M.E. Davis

Affilation: Calando Pharmaceuticals, United States

Pages: 336 - 337

Keywords: siRNA, deliery, RRM2, nanoparticle, transferrin

Abstract:
Calando Pharmaceuticals is developing siRNA-containing nanoparticle formulations, and its leading formulation that will enter the clinic in 2008 contains the human transferrin protein as a targeting ligand and siRNA targeting the M2 subunit of ribonucleotide reductase (RRM2). Critical parameters in the formulation and function of this therapeutic system will be highlighted using data from pre-clinical investigations. Anti-tumor efficacy is enhanced when the targeted version of the nanoparticles are employed, and results from numerous safety and efficacy studies will be discussed.

Systemic Delivery of Targeted, siRNA-Containing Nanoparticles for the Treatment of Solid Tumors: Concept to Clinic

ISBN: 978-1-4200-8504-4
Pages: 808
Hardcopy: $159.95